Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tuberculosis-current therapeutic principles].

U Greinert1, P Zabel

  • 1Medizinische Klinik, Forschungszentrum Borstel. ugreinert@fz-borstel.de

Der Internist
|December 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Yield of dwarf tomatoes grown with a nutrient solution based on recycled synthetic urine.

Life sciences in space research·2019
Same author

Anaphylaxis to vanilla ice cream: a near fatal cross-reactivity phenomenon.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

Review and analysis of over 40 years of space plant growth systems.

Life sciences in space research·2016
Same author

Regional lung function determined by electrical impedance tomography during bronchodilator reversibility testing in patients with asthma.

Physiological measurement·2016
Same author

Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses.

Pneumologie (Stuttgart, Germany)·2016
Same author

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Diagnostic pathology·2015
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Standard and prolonged chemotherapy regimens are crucial for treating active and latent tuberculosis (TB). Drug-resistant TB requires extended treatment with multiple effective drugs, emphasizing reliable delivery and side effect management.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Tuberculosis (TB) treatment requires chemotherapy for both active disease and latent infection.
  • Standard regimens for drug-susceptible TB involve isoniazid and rifampicin, with pyrazinamide and ethambutol added for initial two months.
  • Treatment duration varies based on disease severity and drug resistance patterns.

Purpose of the Study:

  • To outline current chemotherapy indications and standard treatment protocols for tuberculosis.
  • To address the necessity of prolonged treatment in specific complex TB cases.
  • To highlight considerations for multidrug-resistant tuberculosis (MDR-TB) and latent TB infection management.

Main Methods:

  • Review of established chemotherapy guidelines for tuberculosis.

Related Experiment Videos

  • Analysis of treatment duration adjustments for cavernous pulmonary TB, CNS TB, and lymph node TB.
  • Consideration of drug susceptibility testing for MDR-TB treatment selection.
  • Evaluation of treatment strategies for latent tuberculosis infection.

    • Main Results:

    • Standard treatment for drug-susceptible TB is six months of isoniazid and rifampicin, with pyrazinamide and ethambutol for the first two months.
    • Prolonged therapy is essential for cavernous pulmonary TB, CNS TB, and certain lymph node TB cases.
    • MDR-TB necessitates extended treatment with at least three effective, susceptibility-tested drugs.
    • Isoniazid is the classical treatment for latent TB infection; multidrug short-course therapy offers compliance benefits but increased toxicity.

    Conclusions:

    • Effective chemotherapy is vital for managing all forms of tuberculosis, including latent infections.
    • Tailoring treatment duration and drug selection based on clinical presentation and drug resistance is critical.
    • Reliable drug delivery and vigilant monitoring for side effects are paramount in antituberculosis chemotherapy.